NO20005037L - Paroksetinmaleat - Google Patents
ParoksetinmaleatInfo
- Publication number
- NO20005037L NO20005037L NO20005037A NO20005037A NO20005037L NO 20005037 L NO20005037 L NO 20005037L NO 20005037 A NO20005037 A NO 20005037A NO 20005037 A NO20005037 A NO 20005037A NO 20005037 L NO20005037 L NO 20005037L
- Authority
- NO
- Norway
- Prior art keywords
- paroksetinmaleat
- depression
- prevention
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9807627.6A GB9807627D0 (en) | 1998-04-09 | 1998-04-09 | Novel compounds |
| GBGB9823856.1A GB9823856D0 (en) | 1998-10-30 | 1998-10-30 | Novel compound |
| PCT/GB1999/001106 WO1999052901A1 (en) | 1998-04-09 | 1999-04-09 | Paroxetine maleate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005037D0 NO20005037D0 (no) | 2000-10-06 |
| NO20005037L true NO20005037L (no) | 2000-12-05 |
Family
ID=26313449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005037A NO20005037L (no) | 1998-04-09 | 2000-10-06 | Paroksetinmaleat |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1073652A1 (ko) |
| JP (1) | JP2002511466A (ko) |
| KR (1) | KR20010042552A (ko) |
| CN (1) | CN1305474A (ko) |
| AP (1) | AP2000001950A0 (ko) |
| AU (1) | AU3433499A (ko) |
| BG (1) | BG104914A (ko) |
| BR (1) | BR9909529A (ko) |
| CA (1) | CA2327450A1 (ko) |
| EA (1) | EA200001050A1 (ko) |
| HU (1) | HUP0103651A3 (ko) |
| ID (1) | ID26879A (ko) |
| IL (1) | IL138920A0 (ko) |
| NO (1) | NO20005037L (ko) |
| PL (1) | PL343378A1 (ko) |
| SK (1) | SK15032000A3 (ko) |
| TR (1) | TR200002939T2 (ko) |
| WO (1) | WO1999052901A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| GB9827387D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel process |
| GB9827431D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| NL1017421C2 (nl) | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| KR100672184B1 (ko) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| ITTO20060143A1 (it) * | 2006-02-28 | 2007-09-01 | Bridgestone Corp | Pneumatico |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| AU3108097A (en) * | 1997-06-10 | 1998-12-30 | Synthon B.V. | 4-phenylpiperidine compounds |
-
1999
- 1999-04-09 EP EP99915911A patent/EP1073652A1/en not_active Ceased
- 1999-04-09 SK SK1503-2000A patent/SK15032000A3/sk unknown
- 1999-04-09 PL PL99343378A patent/PL343378A1/xx not_active Application Discontinuation
- 1999-04-09 BR BR9909529-7A patent/BR9909529A/pt not_active Application Discontinuation
- 1999-04-09 JP JP2000543459A patent/JP2002511466A/ja active Pending
- 1999-04-09 HU HU0103651A patent/HUP0103651A3/hu unknown
- 1999-04-09 IL IL13892099A patent/IL138920A0/xx unknown
- 1999-04-09 TR TR2000/02939T patent/TR200002939T2/xx unknown
- 1999-04-09 ID IDW20002033A patent/ID26879A/id unknown
- 1999-04-09 KR KR1020007011214A patent/KR20010042552A/ko not_active Application Discontinuation
- 1999-04-09 WO PCT/GB1999/001106 patent/WO1999052901A1/en not_active Application Discontinuation
- 1999-04-09 CN CN99807148A patent/CN1305474A/zh active Pending
- 1999-04-09 AU AU34334/99A patent/AU3433499A/en not_active Abandoned
- 1999-04-09 EA EA200001050A patent/EA200001050A1/ru unknown
- 1999-04-09 CA CA002327450A patent/CA2327450A1/en not_active Abandoned
- 1999-04-09 AP APAP/P/2000/001950A patent/AP2000001950A0/en unknown
-
2000
- 2000-10-06 NO NO20005037A patent/NO20005037L/no not_active Application Discontinuation
- 2000-11-07 BG BG104914A patent/BG104914A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200002939T2 (tr) | 2001-02-21 |
| AP2000001950A0 (en) | 2000-12-31 |
| KR20010042552A (ko) | 2001-05-25 |
| BG104914A (en) | 2001-10-31 |
| SK15032000A3 (sk) | 2001-04-09 |
| PL343378A1 (en) | 2001-08-13 |
| WO1999052901A1 (en) | 1999-10-21 |
| JP2002511466A (ja) | 2002-04-16 |
| HUP0103651A3 (en) | 2002-12-28 |
| ID26879A (id) | 2001-02-15 |
| NO20005037D0 (no) | 2000-10-06 |
| AU3433499A (en) | 1999-11-01 |
| CA2327450A1 (en) | 1999-10-21 |
| HUP0103651A2 (en) | 2002-08-28 |
| CN1305474A (zh) | 2001-07-25 |
| IL138920A0 (en) | 2001-11-25 |
| EA200001050A1 (ru) | 2001-04-23 |
| BR9909529A (pt) | 2000-12-12 |
| EP1073652A1 (en) | 2001-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0531410A4 (en) | (+)--g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl)-4-piperidinemethanol | |
| DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
| CL2004001174A1 (es) | Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia | |
| DE69708149D1 (de) | Doppelkammerbehälter sowie einzelne kammer dafür | |
| IL144294A0 (en) | P53 inhibitors and therapeutic use of the same | |
| NO20003488D0 (no) | Homopolymerer og kopolymerer av etylen | |
| ID21863A (id) | Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak | |
| PT1100459E (pt) | Preparacao oleosa espumante e sua utilizacao | |
| NO20020567D0 (no) | Fremgangsmåte for tillaging og bruk av ozonanriket vann | |
| MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
| DK0871656T3 (da) | Dolastatinderivater, deres fremstilling og anvendelse | |
| PL324750A1 (en) | Expressive construct p16 and posiibility of using it in treating carcinomas | |
| AU2002366201A1 (en) | Use of defined copolymers as adjuvants and agents in the agrotechnical domain | |
| NO20001412D0 (no) | Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser | |
| NO20005037L (no) | Paroksetinmaleat | |
| NO984836L (no) | Substituerte benzylaminer og deres anvendelse for behandling av depresjon | |
| CY2482B1 (en) | Paroxetine in treatment of depression. | |
| NO994257D0 (no) | Anvendelse av levobupivakain ved ansiktskirurgi | |
| IL148202A0 (en) | Copolymers and methods of treating prion-related diseases | |
| ZA972345B (en) | Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders. | |
| IL152908A0 (en) | USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS | |
| IL131085A0 (en) | The use of levobupivacaine or ropivacaine in treating migraine | |
| EE200000290A (et) | Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks | |
| AU3022201A (en) | Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts | |
| AU2002222125A1 (en) | Prevention and treatment of tachyphylactic response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |